Skip to main contentSkip to navigationSkip to search

Interim Report January - March 2022

May 24, 2022


Curasight A/S (“Curasight” or “the Company” - TICKER: CURAS) hereby publishes the interim report for the period January 1 – March 31, 2022. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

Curasight’s CEO Ulrich Krasilnikoff comments:

Curasight began the year by accomplishing several essential milestones and strengthening its position as a theranostic company. Among the highlights are the positive results from the investigator-initiated phase IIb studies regarding Neuroendocrine tumors (NET) and granting of our US patent application relating to uTRACE©. As we add more indications to our clinical development and update our strategy, we stand well-positioned to accelerate our position in cancer management — taking diagnostics and treatment to a new level.”

January – March 2022

  • Net sales amounted to 0 (0) DKK
  • Operating profit/loss amounted to -777,877 (-376,093) DKK
  • Profit/loss before taxes amounted to -1,430,126 (-997,515) DKK
  • Profit/loss for the period amounted to -1,260,714 (-778,065) DKK
  • Total assets amounted to 100,069,057 (61,911,284) DKK
  • Equity ratio amounted to 97.8 (94.3)
  • Earnings per share amounted to -0.06 (-0.05)

Highlights during the first quarter

  • On January 10, Ulrich Krasilnikoff and Andreas Kjær were invited and attended J.P. Morgan 40th Healthcare Conference.
  • On January 18, Ulrich Krasilnikoff and Andreas Kjær presented the Company and its future plans, SEB Nordic Healthcare Seminar 2022.
  • On January 27, Curasight announced that results from an investigator-initiated phase II study performed by researchers at Rigshospitalet using the uTRACE® technology in neuroendocrine tumor patients demonstrate strong prognostic value and support of potential future use of uPAR-targeted radionuclide therapy in these cancers.
  • On February 10, Curasight announced that the Company had signed and completed an agreement to acquire the early-stage R&D company TRT Innovations ApS. Curasight intends to expand and accelerate its clinical programs and is strengthening the therapeutic platform.
  • On February 23, Curasight announced that the Company has expanded its clinical program with two additional indications — Neuroendocrine tumors (NET) and head and neck cancer.

Highlights after the period

  • On April 12, Curasight gave notice of the Annual General Meeting 2022 to be held on April 27, 2022, at the Company’s premises.
  • On April 22, Curasight announced that the United States Patent and Trademark Office has granted Curasight’s United States Patent Application no. 16/870,776 is ready for allowance and the patent will be issued with patent no. 1131137.
  • On April 25, Ulrich Krasilnikoff and Andreas Kjær were invited and attended Sedermeradagen Stockholm. The presentation is available on Sedermeras Youtube channel.
  • On April 27, Curasight held an Annual General Meeting. Resolutions with summarized decisions are available on the company’s website.
  • On May 18, Ulrich Krasilnikoff and Andreas Kjær gave an update on the company’s strategy at Kapital Partner’s Life Science Seminar.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60


Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types.